Agilent Technologies Inc vs MPLX LP — how do they compare? Agilent Technologies Inc trades at $149.35 (market cap $42.00B), while MPLX LP trades at $59.3 (market cap $59.51B). The key difference: MPLX LP is the larger of the two by market cap, and MPLX LP pays the higher dividend (7.34%). Which is the better fit depends on your goals.
| A | MPLX | |
|---|---|---|
Market Cap | $42.00B | $59.51B |
Sector | Health | Technology |
52-Week High | $157.20 | $60.51 |
52-Week Low | $110.24 | $47.80 |
Enterprise Value | $43.55B | $84.62B |
Dividend Yield | 0.69% | 7.34% |
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $145.97, up 3.28% in the last session, with a bullish technical outlook from moving averages but overbought RSI levels. The company reported strong Q1 2026 earnings, beating estimates with EPS of $1.49, and maintains solid profitability with a net income margin of 19.55%. Recent developments include FDA and EU approvals for diagnostic assays and the acquisition of Biocare Medical, enhancing its healthcare portfolio.
The stock offers upside to the consensus price target of $154.90, supported by analyst optimism (77.5% buy ratings), but high valuation ratios like a P/E of 146.56 pose risks. Investors should monitor execution of growth initiatives and competitive pressures in the life sciences sector, with earnings on August 26, 2026, as a key catalyst.
MPLX trades at $58.85, down 2.6% today, with a bullish technical outlook supported by moving averages and strong institutional support. The company maintains robust profitability with 40.45% net income margin and 33.95% ROE, though recent quarters showed mixed earnings performance with two misses. Recent news highlights MPLX's $2.25 billion senior notes offering and solid Q2 2026 results with 5% EBITDA growth.
The stock presents a compelling income opportunity with a 7.3% yield and analyst consensus price target of $61.50 (4.5% upside). Key risks include execution challenges from higher capital spending and leverage concerns, while growth projects in natural gas and NGL services provide multi-year visibility.
Trailing returns across standard periods
Latest headlines on both assets
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →MPLX LP is a Master Limited Partnership (MLP) formed by Marathon Petroleum Corporation (MPC). It is a diversified, growth-oriented company primarily engaged in the gathering, processing, and transportation of natural gas and natural gas liquids (NGLs), as well as the transportation, storage, and distribution of crude oil and refined petroleum products. MPLX owns and operates a network of midstream energy infrastructure assets, providing essential services to the energy industry across the United States.
Read more on MPLX →